CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

SAN ANTONIO--()--CeloNova BioSciences, Inc. (CeloNova) announced today that it has received conditional approval to start an investigational device exemption (IDE) trial to study the COBRA PzF coronary stent system in patients at high risk of bleeding. This is a second major interventional cardiology trial for CeloNova in the U.S., following the successful enrollment of the PzF SHIELD clinical trial earlier this year.

This multicenter, prospective, randomized trial will be referred to as the COBRA-REDUCE trial. Professor Adnan Kastrati, MD., Professor of Medicine at ISAR Research Center, Munich, Germany, is the trial’s Principal Investigator.

The trial will evaluate if the COBRA PzF coronary stent, with its novel Polyzene™-F nano-coating and advanced thin-strut design, can help reduce bleeding as compared to drug eluting stents, by shortening the duration of dual antiplatelet therapy (DAPT) to 14 days in patients treated with oral anticoagulation and undergoing PCI.

“The FDA approval to begin this important trial in the U.S. is another major milestone towards providing compelling clinical evidence to satisfy an unmet market need,” said Jane Ren, Chief Technology Officer at CeloNova. “The COBRA PzF coronary stent system is designed to improve healing and re-endothelialization by reducing thromobogenicity and restenosis in comparison to bare metal stents, without the need for long-term blood thinning agents associated with drug eluting stents.”

In February this year, CeloNova announced accelerated enrollment completion of its PzF SHIELD IDE trial, which will support regulatory submission for FDA approval of the COBRA PzF stent.

“We are encouraged by the initial positive outcomes of the COBRA PzF coronary stent system in initial studies and commercial use outside of the U.S. We look forward to working with the FDA to bring this breakthrough technology to clinicians and patients here in the United States,” said Martin Landon, President and CEO at CeloNova.

The COBRA PzF coronary stent system is an investigational device in the United States. The COBRA PzF coronary stent system received CE Mark approval in 2012 and launched in Europe and the Middle East in 2013.

About the Company

CeloNova BioSciences, Inc., is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Interventional Radiology products. For additional information about CeloNova BioSciences, please visit the company website at http://celonova.com.

Forward-looking statements contained in this press release are based on estimates and assumptions of CeloNova management and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made. We do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied based on a number of factors, including but not limited to, unexpected clinical trial timing and outcomes, results of expanded clinical experience and unanticipated impacts of regulatory decisions.

Contacts

for CeloNova BioSciences, Inc.
Jim Dublin, 210-227-0221
jdublin@dublinandassociates.com

Release Summary

CeloNova BioSciences announces it has received conditional approval to start investigational device exemption (IDE) trial to study COBRA PzF coronary stent system in patients at high risk of bleeding.

Contacts

for CeloNova BioSciences, Inc.
Jim Dublin, 210-227-0221
jdublin@dublinandassociates.com